Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neurofibroma, Plexiform 3Neurofibromatosis 1 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Radiation Fibrosis Syndrome 1Precancerous Conditions 1Pneumonia 1Neurofibromatoses 1Nerve Sheath Neoplasms 1Neoplasms 1Myofibroma 1Lymphedema 1Leiomyoma 1Colorectal Neoplasms 1Acute Lung Injury 1

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 388Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × pirfenidone × Clear all
NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Harbin Medical University

Phase 1/2 Not yet recruiting
12 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05704166 2025-08-08

PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients

Fujian Medical University Union Hospital

Phase 2 Recruiting
214 enrolled
Breast

Breast Neoplasms, Acute Lung Injury

Data powered by HemOnc (CC BY 4.0) Colophon âš¡